Literature DB >> 26802469

Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury.

Yuki Tanaka1, Shinji Kume2, Masami Chin-Kanasaki1, Hisazumi Araki1, Shin-Ichi Araki1, Satoshi Ugi1, Takeshi Sugaya3, Takashi Uzu1, Hiroshi Maegawa1.   

Abstract

Dipeptidyl peptidase (DPP)-4 inhibitors, a new class of antidiabetic agent, have recently been suggested to exert pleiotropic effects beyond glucose lowering. Renal prognosis in patients with diabetic nephropathy depends on the severity of tubulointerstitial injury induced by massive proteinuria. We thus examined the renoprotective effect of DPP-4 inhibitors on inflammation in cultured mouse proximal tubular cells stimulated with free fatty acid (FFA)-bound albumin. Linagliptin and higher concentrations of sitagliptin, vildagliptin, and alogliptin all inhibited FFA-bound albumin-induced increases in mRNA expression of MCP-1 in cultured mouse proximal tubular cells. Furthermore, linagliptin significantly inhibited tubulointerstitial injury induced by peritoneal injection of FFA-bound albumin, such as inflammation, fibrosis, and apoptosis, in mice without altering systemic characteristics including body weight, fasting blood glucose, and food intake. These results indicate that DPP-4 inhibitors pleiotropically exert a direct renoprotective effect, and may serve as an additional therapeutic strategy to protect proximal tubular cells against proteinuria in patients with diabetic nephropathy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Albuminuria; DPP–4 inhibitors; Diabetic nephropathy; Free fatty acid; Proximal tubular cell

Mesh:

Substances:

Year:  2016        PMID: 26802469     DOI: 10.1016/j.bbrc.2016.01.109

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation.

Authors:  Bin Zhang; Xuelian Zhang; Chenyang Zhang; Guibo Sun; Xiaobo Sun
Journal:  Pharm Res       Date:  2021-11-12       Impact factor: 4.200

2.  Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.

Authors:  Seung Hee Choi; Jaechan Leem; In-Kyu Lee
Journal:  Mediators Inflamm       Date:  2017-11-28       Impact factor: 4.711

Review 3.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

Review 4.  Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.

Authors:  Sandra Rayego-Mateos; José Luis Morgado-Pascual; Lucas Opazo-Ríos; Melania Guerrero-Hue; Cristina García-Caballero; Cristina Vázquez-Carballo; Sebastián Mas; Ana Belén Sanz; Carmen Herencia; Sergio Mezzano; Carmen Gómez-Guerrero; Juan Antonio Moreno; Jesús Egido
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

5.  Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.

Authors:  Munehiro Kitada; Yoshio Ogura; Kyoko Nitta; Mizue Fujii; Keizo Kanasaki; Kazunori Konishi; Yasuo Iida; Atsushi Nakagawa; Daisuke Koya
Journal:  J Diabetes Investig       Date:  2018-10-01       Impact factor: 4.232

6.  Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner.

Authors:  Munehiro Kitada; Shin-Ichi Tsuda; Kazunori Konishi; Ai Takeda-Watanabe; Mizue Fujii; Keizo Kanasaki; Makoto Nishizawa; Atsushi Nakagawa; Daisuke Koya
Journal:  BMJ Open Diabetes Res Care       Date:  2017-07-07

7.  DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness.

Authors:  Peir-In Liang; Bi-Wen Yeh; Wei-Ming Li; Ti-Chun Chan; I-Wei Chang; Chun-Nung Huang; Ching-Chia Li; Hung-Lung Ke; Hsin-Chih Yeh; Wen-Jeng Wu; Chien-Feng Li
Journal:  Oncotarget       Date:  2017-01-10

8.  Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats.

Authors:  Jian Xu; Jingjing Wang; Yusheng Cheng; Xiang Li; Mengyu He; Jiali Zhu; Honghao Han; Guihong Wei; Hui Kong; Weiping Xie; Hong Wang; Xiangrong Zuo
Journal:  Biomed Res Int       Date:  2018-01-23       Impact factor: 3.411

9.  Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.

Authors:  Masakazu Haneda; Takashi Kadowaki; Hiroshi Ito; Kazuyo Sasaki; Sonoe Hiraide; Manabu Ishii; Miyuki Matsukawa; Makoto Ueno
Journal:  Diabetes Ther       Date:  2018-04-10       Impact factor: 2.945

10.  Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study.

Authors:  Takamasa Iwakura; Hirotaka Fukasawa; Atsushi Kitamura; Kento Ishibuchi; Hideo Yasuda; Ryuichi Furuya
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.